Large soluble oligomers of amyloid β-protein from alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate

Journal of Neuroscience

Volumn 37, Issue 1, 2017, Pages 152-163

  Yang, Ting ^a   Li, Shaomin ^a   Xu, Huixin ^a   Walsh, Dominic M ^a   Selkoe, Dennis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer s; A aggregation; Long term potentiation; Microglia activation; Size exclusion chromatography; 2 adrenergic receptor

Indexed keywords

AMYLOID BETA PROTEIN; BETA 2 ADRENERGIC RECEPTOR; BUFFER; OLIGOMER;

ALZHEIMER DISEASE; ARTICLE; ELECTROPHYSIOLOGICAL PROCEDURES; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIPPOCAMPAL SLICE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIZE EXCLUSION CHROMATOGRAPHY; WESTERN BLOTTING; ANIMAL; BRAIN CHEMISTRY; C57BL MOUSE; CHEMISTRY; HIPPOCAMPUS; IN VITRO STUDY; LONG TERM POTENTIATION; METABOLISM; MOLECULAR WEIGHT; PATHOPHYSIOLOGY; SYNAPTOSOME; ADULT; AGED; ALKALINITY; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; BIOASSAY; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DEATH; DISSOCIATION; IN VIVO STUDY; MICROGLIA; MIDDLE AGED; NERVE CELL; NERVE CELL STIMULATION; NEUROTOXICITY; PROTEIN ASSEMBLY; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; VERY ELDERLY; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN CHEMISTRY; CHROMATOGRAPHY, GEL; FEMALE; HIPPOCAMPUS; HUMANS; IN VITRO TECHNIQUES; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; RECEPTORS, ADRENERGIC, BETA-2; SYNAPTOSOMES;

EID: 85008953006     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1698-16.2016     Document Type: Article

References (41)

1. Barry AE, Klyubin I, McDonald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ (2011) Alzheimer’s disease brain-derived amyloidbeta-mediated inhibition ofLTP in vivo is preventedbyimmunotargeting cellular prion protein. J Neurosci 31:7259-7263. Cross Ref Medline
2. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367:795-804. Cross Ref Medline
3. Borlikova GG, Trejo M, Mably AJ, McDonald JM, SalaFrigerio C, Regan CM, Murphy KJ, Masliah E, Walsh DM (2013) Alzheimerbrain-derivedam- yloid beta-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging34:1315-1327. Cross Ref Medline
4. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL (2014) Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 17:131-143. Cross Ref Medline
5. Cahill L, Pham CA, Setlow B (2000) Impairedmemoryconsolidationinrats produced with beta-adrenergic blockade. Neurobiol Learn Mem 74:259-266. Cross Ref Medline
6. Chamberlain SR, Muller U, Blackwell AD, Robbins TW, Sahakian BJ (2006) Noradrenergic modulation of working memory and emotional memory in humans. Psychopharmacology 188:397-407. Cross Ref Medline
7. Freir DB, Nicoll AJ, Klyubin I, Panico S, McDonald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J (2011) Interaction between prion protein and toxic amyloid betaassemblies canbe therapeuticallytargeted at multiple sites. Nat Commun 2:336.Cross Ref Medline
8. Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM (2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer’s disease. Neurobiol Aging 28:327-335. Cross Ref Medline
9. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112.
10. Cross Ref MedlineHu NW, Nicoll AJ, Zhang D, Mably AJ, O’Malley T, Purro SA, Terry C, Collinge J, Walsh DM, Rowan MJ (2014) mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo. Nat Commun 5:33-74. Cross Ref Medline
11. Hyman BT, West HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, Stanley HE (1995) Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci U S A 92:3586-3590. Cross Ref Medline
12. Jack CR Jr, Holtzman DM (2013) Biomarker modeling of Alzheimer’s disease. Neuron 80:1347-1358. Cross Ref Medline
13. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108:5819-5824. Cross Ref Medline
14. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556-561. Cross Ref Medline
15. Klyubin I, Nicoll AJ, Khalili-Shirazi A, Farmer M, Canning S, Mably A, Line- han J, Brown A, Wakeling M, Brandner S, Walsh DM, Rowan MJ, Col- linge J (2014) Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer’s disease Abeta synaptotoxicity. J Neurosci 34:6140-6145. Cross Ref Medline
16. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL (2009) Oligomeric amyloid beta associates with post-synaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad SciUSA 106:4012-4017. Cross Ref Medline
17. Lannfelt L, Moller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P (2014) Perspectives on future Alzheimer therapies: amyloid-beta protofibrils: a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimers Res Ther 6:16. Cross Ref Medline
18. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid beta protein facilitate hippocampal longterm depression by disrupting neuronal glutamate uptake. Neuron 62: 788-801. Cross Ref Medline
19. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011) Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci31:6627-6638. Cross Ref Medline
20. Li S, Jin M, Zhang D, Yang T, Koeglsperger T, Fu H, Selkoe DJ (2013) Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron 77:929-941. Cross Ref Medline
21. Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, Soderberg L, Moller C, Gellerfors P, Lannfelt L, Pettersson FE, Nilsson LN (2009) An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s disease. Neurobiol Dis 36:425-434. Cross Ref Medline
22. Mably AJ, Liu W, McDonald JM, Dodart JC, Bard F, Lemere CA, O’Nuallain B, Walsh DM (2015) Anti-Abeta antibodies incapable ofreducing cerebral Abeta oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol Dis 82:372-384. Cross Ref Medline
23. Manaye KF, Mouton PR, Xu G, Drew A, Lei DL, Sharma Y, Rebeck GW, Turner S (2013) Age-related loss ofnoradrenergic neurons in the brains of triple transgenic mice. Age 35:139-147. Cross Ref Medline
24. Marien MR, Colpaert FC, Rosenquist AC (2004) Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev 45:38-78. Cross Ref Medline
25. McDonald JM, O’Malley TT, Liu W, Mably AJ, Brinkmalm G, Portelius E, Wittbold WM 3rd, Frosch MP, Walsh DM (2015) Theaqueousphaseof Alzheimer’s disease brain contains assemblies built from approximately 4 and approximately 7 kDa Abeta species. Alzheimers Dement 11:1286-1305. Cross Ref Medline
26. O’Malley TT, Oktaviani NA, Zhang D, Lomakin A, O’Nuallain B, Linse S, Benedek GB, Rowan MJ, Mulder FA, Walsh DM (2014) Abeta dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. Biochem J 461:413-426. Cross Ref Medline
27. O’Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM (2010) Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 30:14411-14419. Cross Ref Medline
28. Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Eng- ber T, et al. (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature 537:50-56. Cross Ref Medline
29. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. NatMed 14:837-842. Cross Ref Medline
30. Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM (2011) Isolation oflow-n amyloid beta-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol 670:33-44. Cross Ref Medline
31. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA (2006) Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer’s disease and dementia with Lewy bodies. J Neurosci 26:467-478. Cross Ref Medline
32. Upadhaya AR, Lungrin I, Yamaguchi H, Fändrich M, Thal DR (2012) High- molecular weight Abeta oligomers and protofibrils are the predominant Abeta species in the native soluble protein fraction of the AD brain. J Cell Mol Med 16:287-295. Cross Ref Medline
33. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Masters CL (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12:357-367. Cross Ref Medline
34. Walsh DM, Selkoe DJ (2004) Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11: 213-228. Cross Ref Medline
35. Walsh DM, Selkoe DJ (2007) Abeta oligomers: a decade of discovery. J Neu- rochem 101:1172-1184. Cross Ref Medline
36. Wang D, Yuen EY, Zhou Y, Yan Z, Xiang YK (2011) Amyloid beta peptide- (1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons. J Biol Chem 286:31852-31863. Cross Ref Medline
37. Weinshenker D (2008) Functional consequences of locus coeruleus degeneration in Alzheimer’s disease. Curr Alzheimer Res 5:342-345. Cross Ref Medline
38. Xia W, Yang T, Shankar G, Smith IM, She, Y, Walsh DM, Dennis J, Selkoe M (2009) A specific enzyme-linked immunosorbent assay for measuring ß-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66:190-199. Cross Ref Medline
39. Xu H, Gelyana E, Rajsombath M, Yang T, Li S, Selkoe D (2016) Environmental enrichment potently prevents microglia-mediated neuroinflammation by human amyloid beta-protein oligomers. J Neurosci 36: 9041-9056. Cross Ref Medline
40. Yang T, Hong S, O’Malley T, Sperling RA, Walsh DM, Selkoe DJ (2013) New ELISAs with high specificity for soluble oligomers of amyloid betaprotein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement 9:99-112. Cross Ref Medline
41. Yang T, O’Malley TT, Kanmert D, Jerecic J, Zieske LR, Zetterberg H, Hyman BT, Walsh DM, Selkoe DJ (2015) A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res Ther 7:14. Cross Ref Medline